Skip to main content

Boston Scientific Corporation (BSX) Stock Analysis

Falling Knife setup · Temp Headwind edge

Buy WaitAI GATE: FLAGGED — 1 risk, 1 concernModerate Confidence

Healthcare · Medical Devices

Wait — supporting gate not met yet. Price is at or below entry $57.95 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Negative momentum; Below 200-MA, MA slope -6.1%/30d (confirmed downtrend).

Boston Scientific develops, manufactures, and markets medical devices across interventional medical specialties globally for more than 45 years, with international net sales representing 36% of global net sales in 2025. Revenue is generated from selling devices to hospitals,... Read more

$56.58+44.6% A.UpsideScore 6.3/10#2 of 40 Medical Devices
Entry $57.95(Atr Pullback Sticky)Stop $53.07Target $78.37(analyst − 8%)A.R:R 4.5:1
Analyst target$85.19+50.6%32 analysts
$78.37our TP
$56.58price
$85.19mean
$110

Wait — supporting gate not met yet. Price is at or below entry $57.95 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Negative momentum; Below 200-MA, MA slope -6.1%/30d (confirmed downtrend). Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.71, quality 8.4/10, growth 7.7/10). Score 6.3/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 83d clear, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

Val7.0Qual8.4Grw7.7Mom1.1Sent8.5Ins5.0Peer4.3Tech6.6Risk6.96.3OVERALL

Thesis

Rewards
Strong earnings beat streak (4/4)
High-quality business
Attractive valuation
Risks
Negative momentum
Below 200-MA, MA slope -6.1%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)23.9
P/E (Fwd)15.2
Mkt Cap$84.9B
EV/EBITDA17.5
Profit Mgn17.3%
ROE—
Rev Growth11.6%
Beta0.78
DividendNone
Rating analysts41

Quality Signals

Piotroski F9/9

Options Flow

P/C0.40bullish
IV45%normal
Max Pain$50-11.6% vs spot

Material Events(8-K, last 90d)

  • 2026-02-26Item 1.01LOW
    BSX entered into a new $3.0B revolving credit agreement with Wells Fargo as administrative agent, maturing February 26, 2031, with one-year extension options. Routine refinancing of prior credit facility.
    SEC filing →
  • 2026-02-26Item 1.02MEDIUM
    Termination of prior material credit agreement concurrent with entry into the new $3.0B revolving credit facility dated February 26, 2026. Routine replacement as part of refinancing.
    SEC filing →
  • 2026-02-23Item 5.02LOW
    Board increased from 10 to 12 directors; Catherine R. Smith and Christophe P. Weber appointed as directors effective February 18, 2026. Standard non-employee director compensation applies.
    SEC filing →
  • 2026-02-05Item 5.02LOW
    Director Yoshiaki Fujimori informed BSX he will not stand for re-election at the 2026 Annual Meeting; will continue serving until then. No disagreement with the Company cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.0
Obv
1.0
Ma Position
1.0
Rsi
3.5
Volume distribution (falling OBV)Below 200-MA, MA slope -6.1%/30d — confirmed downtrend
GatesMomentum 1.1<4.5Death cross (50MA < 200MA)A.R:R 4.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 83d clearSEMI CYCLE PEAK CLEARFalling KnifeSuitability: Moderate
RSI
40 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $56.05Resistance $66.88

Price Targets

$53
$58
$78
A.Upside+38.5%
A.R:R4.5:1

Position Sizing

ConvictionHigh conviction
Suggested %0.7%
Max %1.3%
RegimeSteady

Risk Alerts

! Momentum score 1.1/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA
! News gate: flagged (1 risks, 1 concerns)

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-07-22 (83d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is BSX stock a buy right now?

Wait — supporting gate not met yet. Price is at or below entry $57.95 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Negative momentum; Below 200-MA, MA slope -6.1%/30d (confirmed downtrend). Chart setup: Death cross, below all MAs, RSI 40, MACD bearish. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.71, quality 8.4/10, growth 7.7/10). Target $78.37 (+38.5%), stop $53.07 (−6.6%), Setup A.R:R 6.4:1. Score 6.3/10, moderate confidence.

What is the BSX stock price target?

Take-profit target: $78.37 (+44.6% upside). Target $78.37 (+38.5%), stop $53.07 (−6.6%), Setup A.R:R 6.4:1. Stop-loss: $53.07.

What are the risks of investing in BSX?

Negative momentum; Below 200-MA, MA slope -6.1%/30d (confirmed downtrend).

Is BSX overvalued or undervalued?

Boston Scientific Corporation trades at a P/E of 23.9 (forward 15.2). TrendMatrix value score: 7.0/10. Verdict: Buy (Wait for Entry).

What do analysts say about BSX?

41 analysts cover BSX with a consensus score of 4.2/5. Average price target: $85.

What does Boston Scientific Corporation do?Boston Scientific develops, manufactures, and markets medical devices across interventional medical specialties...

Boston Scientific develops, manufactures, and markets medical devices across interventional medical specialties globally for more than 45 years, with international net sales representing 36% of global net sales in 2025. Revenue is generated from selling devices to hospitals, physicians, and other healthcare providers across cardiology, urology, endoscopy, and adjacent specialties.

Related stocks: GMED (Globus Medical, Inc.) · DXCM (DexCom, Inc.) · ZBH (Zimmer Biomet Holdings, Inc.) · PEN (Penumbra, Inc.) · SNN (Smith & Nephew SNATS, Inc.)